Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial

INTRODUCTION: Crohn’s disease (CD) is a chronic inflammatory bowel disease with a heterogeneous clinical presentation, relapse rate and treatment response. At present, no markers are available to adequately predict disease course at diagnosis. To prevent overtreatment of patients with a relative mil...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Laura, Romberg-Camps, Mariëlle, van Bodegraven, Ad, Haans, Jeoffrey, Aquarius, Michèl, Boekema, Paul, Munnecom, Tamara, Brandts, Lloyd, Joore, Manuela, Masclee, Adrian, Jonkers, D, Pierik, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098960/
https://www.ncbi.nlm.nih.gov/pubmed/33947729
http://dx.doi.org/10.1136/bmjopen-2020-042885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098960/
https://www.ncbi.nlm.nih.gov/pubmed/33947729
http://dx.doi.org/10.1136/bmjopen-2020-042885

Ejemplares similares